Jazz Pharmaceuticals plc's latest marketcap:
As of 07/05/2025, Jazz Pharmaceuticals plc's market capitalization has reached $6.62 B. According to our data, Jazz Pharmaceuticals plc is the 2702th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 6.62 B |
| Revenue (ttm) | 4.06 B |
| Net Income (ttm) | 482.2 M |
| Shares Out | 60.51 M |
| EPS (ttm) | 7.51 |
| Forward PE | 13.86 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/30/2025 |
Jazz Pharmaceuticals plc's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $6.62 B | -9% | 2702 |
| 12/31/2024 | $7.44 B | -3.86% | 2195 |
| 12/29/2023 | $7.74 B | -22.8% | 2024 |
| 12/30/2022 | $10.03 B | 28.09% | 1514 |
| 12/31/2021 | $7.83 B | -14.84% | 2215 |
| 12/31/2020 | $9.2 B | 8.89% | 1733 |
| 12/31/2019 | $8.45 B | 12.94% | 1557 |
| 12/31/2018 | $7.48 B | -7.37% | 1479 |
| 12/29/2017 | $8.07 B | 23.62% | 1571 |
| 12/30/2016 | $6.53 B | -24.46% | 1515 |
Company Profile
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies. Headquartered in Dublin, Ireland, the company operates in the United States, Europe, and internationally.
Key Products
- Xywav – Treats cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH).
- Xyrem – Addresses cataplexy or EDS in narcolepsy patients.
- Epidiolex – Used for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC).
- Rylaze & Enrylaze – Treat acute lymphoblastic leukemia and lymphoblastic lymphoma.
- Zepzelca – Targets metastatic small cell lung cancer post-platinum-based chemotherapy.
- Ziihera – Addresses HER2-positive biliary tract cancers.
- Defitelio – Used for severe veno-occlusive disease.
- Vyxeos – Treats newly-diagnosed therapy-related acute myeloid leukemia.
Pipeline Highlights
- Zanidatamab – Phase 3 trial for HER2-expressing gastroesophageal adenocarcinoma (GEA).
- Epidiolex – Phase 3 trial for LGS, DS, and TSC.
- Suvecaltamide – Phase 2 trial for Parkinson's disease tremor.
- JZP815 – Phase 1 pan-RAF kinase inhibitor targeting MAP kinase.
- JZP898 – Phase 1 conditionally activated interferon alpha molecule.
- JZP441 – Phase 1 trial for narcolepsy, IH, and sleep disorders.
- JZP324 – Phase 1 extended-release low sodium oxybate for sleep disorders.
- JZP150 – Investigational treatment for post-traumatic stress disorder.
Strategic Collaborations
Jazz Pharmaceuticals has licensing and collaboration agreements with:
- Redx Pharma plc
- Autifony Therapeutics Limited
- Zymeworks Inc.
- Sumitomo Pharma Co., Ltd.
- Werewolf Therapeutics, Inc.
Founded in 2003, Jazz Pharmaceuticals continues to advance its mission of delivering life-changing therapies to patients worldwide.
Frequently Asked Questions
-
What is Jazz Pharmaceuticals plc's (JAZZ) current market cap?As of 07/05/2025, Jazz Pharmaceuticals plc (including the parent company, if applicable) has an estimated market capitalization of $6.62 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Jazz Pharmaceuticals plc (JAZZ) rank globally by market cap?Jazz Pharmaceuticals plc global market capitalization ranking is approximately 2702 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.